Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib in active Crohn's disease
NCT07403968Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zasocitinib in Crohn's disease, sponsored by Takeda. Started Aug 2026; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07403968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07403968.